Eli Lilly’s revenues
Eli Lilly and Company (LLY) reported revenues of $5.7 billion in 3Q17, a 9% growth compared to 3Q16. It surpassed Wall Street analysts’ estimates for EPS (earnings per share) and revenues in 3Q17. EPS was $1.05, and revenues were $5.7 billion compared to the estimated EPS of $1.03 on revenues of $5.5 billion.
The above graph compares Eli Lilly’s revenue trend over the last eight quarters. For 4Q17, analysts estimate revenues of $5.9 billion, a 3% growth compared to 4Q16. We’ll look at the detailed estimates for 4Q17 and 2017 later in this series.
In 3Q17, Eli Lilly’s top line increased 9% to $5.7 billion. Growth was driven by the strong performances of its human pharmaceuticals and animal health products portfolios. Its net income rose 19% to $1.1 billion in 3Q17 compared to 3Q16.
US markets contributed 55% of Eli Lilly’s total revenues in 3Q17. US sales rose 9% to $3.1 billion in 3Q17 compared to 3Q16. Growth in US sales was driven by strong sales of Basaglar, Lartruvo, Jardiance, Taltz, and a few other pharmaceutical products. It was also driven by companion animal products and the inclusion of revenues from its acquired vaccines portfolio from Boehringer Ingelheim.
Its international markets reported an 8% growth in sales to ~$2.6 billion in 3Q17 compared to 3Q16. Growth was driven by strong sales of Forteo and Humalog.
We’ll look at each segment’s performance for 3Q17 later in this series.